Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.

Author: JainHemat, KumavatVandana, SarneckiMichal, SinghTejinder, VersteilenAmanda

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study compared the immunogenicity and safety of a virosomal hepatitis A vaccine (HAVpur Junior) and an aluminum-adsorbed vaccine (Havrix 720 Junior) in Indian children. Both vaccines induced similar immune responses and were well tolerated. The study supports the use of HAVpur Junior in Indian childhood vaccination schedules.
Paper Details　
Original Abstract of the Article :
As India is transitioning from high to intermediate hepatitis A endemicity, the need for hepatitis A vaccination programs increases. This study investigated the immunogenicity and safety of a virosomal hepatitis A vaccine (HAVpur Junior) compared with an aluminum-adsorbed hepatitis A vaccine (Havrix...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186045/

データ提供：米国国立医学図書館（NLM）

Hepatitis A Vaccination in India: Comparing Virosomal and Aluminum-Adsorbed Vaccines in Children

This study examines the immunogenicity and safety of two hepatitis A vaccines, a virosomal vaccine (HAVpur Junior) and an aluminum-adsorbed vaccine (Havrix 720 Junior), in healthy Indian children. The researchers conducted a randomized trial to compare the immune responses and safety profiles of these two vaccines in children aged 18-47 months.

Hepatitis A Vaccines: Ensuring Protection for Children

The study demonstrated that both HAVpur Junior and Havrix 720 Junior were effective in inducing protective levels of antibodies against hepatitis A virus in Indian children. The virosomal vaccine HAVpur Junior, which is aluminum-free, showed non-inferiority compared to the aluminum-adsorbed Havrix 720 Junior, suggesting that both vaccines are safe and effective in protecting children against hepatitis A.

Hepatitis A: Ensuring Protection in Vulnerable Populations

This research is particularly important for India, which is transitioning from high to intermediate hepatitis A endemicity. The findings provide valuable information for developing effective vaccination programs to protect children in this vulnerable population.

Dr. Camel's Conclusion

Just like a camel navigating a changing desert landscape, India is facing a shift in the prevalence of hepatitis A. This study provides important insights into the effectiveness of different hepatitis A vaccines in protecting children, offering valuable information for public health initiatives in India.

Date :
  1. Date Completed 2016-02-22
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25424821

DOI: Digital Object Identifier

PMC4186045

Related Literature

Article Analysis
・Side Effects of hepatitis a vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.